The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
Open accessAbstract
Background and Aims: Metabolic-associated fatty liver disease (MAFLD) was proposed as a better definition of nonalcoholic fatty liver disease (NAFLD) to encompass the metabolic dysregulation associated with NAFLD. This redefinition challenges our understanding of the disease. Hence, this study sought to conduct an updated analysis of the prevalence, clinical characteristics, and associated factors of MAFLD, with a further sensitivity analysis done based on lean and nonobese MAFLD individuals. Methods: Medline and Embase databases were searched to include articles on MAFLD. Meta-analysis of proportions was conducted using the generalized linear mix model. Associating factors were evaluated in conventional pairwise meta-analysis with sensitivity analysis on lean and nonobese MAFLD. Results: From pooled analysis involving 3 320 108 individuals, the overall prevalence of MAFLD was 38.77% (95% CI 32.94% to 44.95%); 5.37% (95% CI 4.36% to 6.59%) and 29.78% (95% CI 26.06% to 33.79%) of lean and nonobese individuals, respectively, had MAFLD. Metabolic complications such as hypertension [odds ratio (OR) 2.63, 95% CI 1.85 to 3.74, P < 0.0001 and OR 2.03; 95% CI 1.74 to 2.38, P < 0.0001, respectively] and diabetes (OR 3.80, 95% CI 2.65 to 5.43, P < 0.0001 and OR 3.46, 95% CI 2.81 to 4.27, P < 0.0001, respectively) were found as significant associating factors associated with lean and nonobese MAFLD. Conclusions: This meta-analysis supports previous studies in reporting MAFLD to affect more than a third of the global population. While exploration of the pathogenic basis of fatty liver disease without metabolic dysregulation is required, the emphasis on management of concomitant metabolic disease in MAFLD can improve multidisciplinary efforts in managing the complex disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Loomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Munn, Z., Moola, S., Riitano, D., & Lisy, K. (2014) · International Journal of Health Policy and Management · doi:10.15171/ijhpm.2014.71 · Cited by 1,479
Fixed and random effects models: making an informed choice
Bell, A., Fairbrother, M., & Jones, K. (2019) · Quality & Quantity · doi:10.1007/s11135-018-0802-x · Cited by 1,085
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Tufanaru, C., Munn, Z., Stephenson, M., & Aromataris, E. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000065 · Cited by 1,057
Li, J., Zou, B., Yeo, Y. H., Feng, Y., Xie, X., Lee, D. H., Fujii, H., Wu, Y., Kam, L. Y., Ji, F., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30039-1 · Cited by 1,031
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925
Self-citationEslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Self-citation2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Self-citationSchwarzer, G., Chemaitelly, H., Abu‐Raddad, L. J., & Rücker, G. (2019) · Research Synthesis Methods · doi:10.1002/jrsm.1348 · Cited by 625
What is heterogeneity and is it important?
Fletcher, J. (2007) · BMJ · doi:10.1136/bmj.39057.406644.68 · Cited by 546
Past, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
Lee, H., Lee, Y.-H., Kim, S. U., & Kim, H. C. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.12.022 · Cited by 463
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T. (2020) · Liver International · doi:10.1111/liv.14675 · Cited by 401
Sun, D.-Q., Jin, Y., Wang, T.-Y., Zheng, K. I., Rios, R. S., Zhang, H.-Y., Targher, G., Byrne, C. D., Yuan, W.-J., & Zheng, M.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154433 · Cited by 308
What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’
Fouad, Y., Waked, I., Bollipo, S., Gomaa, A., Ajlouni, Y., & Attia, D. (2020) · Liver International · doi:10.1111/liv.14478 · Cited by 295
From NAFLD to MAFLD: when pathophysiology succeeds
Tilg, H., & Effenberger, M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0316-6 · Cited by 257
Lim, G. E. H., Tang, A., Ng, C. H., Chin, Y. H., Lim, W. H., Tan, D. J. H., Yong, J. N., Xiao, J., Lee, C. W.-M., Chan, M., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.11.038 · Cited by 246
Self-citationLiu, J., Ayada, I., Zhang, X., Wang, L., Li, Y., Wen, T., Ma, Z., Bruno, M. J., de Knegt, R. J., Cao, W., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.02.030 · Cited by 242
Guo, B., Guo, Y., Nima, Q., Feng, Y., Wang, Z., Lu, R., Baimayangji, Ma, Y., Zhou, J., Xu, H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.016 · Cited by 237
Kushner, R. F., & Ryan, D. H. (2014) · JAMA · doi:10.1001/jama.2014.10432 · Cited by 235
What is driving global obesity trends? Globalization or “modernization”?
Fox, A., Feng, W., & Asal, V. (2019) · Globalization and Health · doi:10.1186/s12992-019-0457-y · Cited by 222
Wong, V. W.-S., Wong, G. L.-H., Woo, J., Abrigo, J. M., Chan, C. K.-M., Shu, S. S.-T., Leung, J. K.-Y., Chim, A. M.-L., Kong, A. P.-S., Lui, G. C.-Y., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.046 · Cited by 192
Ciardullo, S., & Perseghin, G. (2021) · Liver International · doi:10.1111/liv.14828 · Cited by 191
Nonalcoholic fatty liver disease: Definitions, risk factors, and workup
Puri, P., & Sanyal, A. J. (2012) · Clinical Liver Disease · doi:10.1002/cld.81 · Cited by 174
Tsutsumi, T., Eslam, M., Kawaguchi, T., Yamamura, S., Kawaguchi, A., Nakano, D., Koseki, M., Yoshinaga, S., Takahashi, H., Anzai, K., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13685 · Cited by 170
Self-citationHistory of Nonalcoholic Fatty Liver Disease
Lonardo, A., Leoni, S., Alswat, K., & Fouad, Y. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165888 · Cited by 169
Shiha, G. E.-S., Alswat, K., Khatry, M. A., Sharara, A. I., Örmecı, N., Waked, I. A., Benazzouz, M., Al-Ali, F., Hamed, A. E., Hamoudi, W., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30213-2 · Cited by 156
Méndez‐Sánchez, N., Arrese, M. A., Gadano, A. C., de Oliveira, C. P. M. S., Fassio, E., Arab, J. P., Chávez-Tapia, N. C., Dirchwolf, M., Torre, A., Ridruejo, E., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30340-x · Cited by 149
Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers
Liu, Z., Lin, C., Suo, C., Zhao, R., Li, J., Zhang, T., & Chen, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154955 · Cited by 131
Toh, J. Z. K., Pan, X.-H., Tay, P. W. L., Ng, C. H., Yong, J. N., Xiao, J., Koh, J. H., Tan, E. Y., Tan, E. X. X., Dan, Y. Y., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.021 · Cited by 130
Self-citationvan Kleef, L. A., Choi, H. S. J., Brouwer, W. P., Hansen, B. E., Patel, K., de Man, R. A., Janssen, H. L. A., de Knegt, R. J., & Sonneveld, M. J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100350 · Cited by 126
NAFLD and MAFLD as emerging causes of HCC: A populational study
Myers, S., Neyroud‐Caspar, I., Spahr, L., Gkouvatsos, K., Fournier, E., Giostra, E., Magini, G. M., Frossard, J., Bascaron, M.-E., Vernaz, N., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100231 · Cited by 122
Muthiah, M. D., Han, N. C., & Sanyal, A. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14521 · Cited by 114
Self-citationChen, Y., Li, H., Li, S., Xu, Z., Tian, S., Wu, J., Liang, X., Li, X., Liu, Z., Xiao, J., et al. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01782-w · Cited by 113
Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study
Niriella, M. A., Ediriweera, D. S., Kasturiratne, A., Silva, S. D., Dassanayaka, A. S., Silva, A. P. D., Kato, N., Pathmeswaran, A., Wickramasinghe, A. R., & de Silva, H. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245762 · Cited by 104
Yoneda, M., Yamamoto, T., Honda, Y., Imajo, K., Ogawa, Y., Kessoku, T., Kobayashi, T., Nogami, A., Higurashi, T., Kato, S., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01828-6 · Cited by 96
Wang, X., Wu, S., Yuan, X., Chen, S., Fu, Q., Sun, Y., Lan, Y., Hu, S., Wang, Y., Lu, Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab644 · Cited by 82
Quek, J., Ng, C. H., Tang, A. S. P., Chew, N., Chan, M. Y., Khoo, C. M., Wei, C. P., Chin, Y. H., Tay, P. W. L., Lim, G., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.016 · Cited by 80
Self-citationMoon, J. H., Kim, W. K., Koo, B. K., & Cho, N. H. (2021) · Gut and Liver · doi:10.5009/gnl210167 · Cited by 79
Eren, F., Kaya, E., & Yilmaz, Y. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001946 · Cited by 71
Burden of Disease due to Nonalcoholic Fatty Liver Disease
Muthiah, M. D., & Sanyal, A. J. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.09.007 · Cited by 70
Self-citationFouad, Y. M., Gomaa, A., Semida, N., Ghany, W. A., & Attia, D. I. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.035 · Cited by 66
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro, G. T. S., Longo, L., Fonseca, M. A., de Souza, V. E. G., & Álvares‐da‐Silva, M. R. (2021) · Hepatology International · doi:10.1007/s12072-021-10157-y · Cited by 65
Fan, J., Luo, S., Ye, Y., Ju, J., Zhang, Z., Liu, L., Yang, J., & Xia, M. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00611-x · Cited by 65
Liver Fibrosis in Asians With Metabolic Dysfunction–Associated Fatty Liver Disease
Sohn, W., Kwon, H., Chang, Y., Ryu, S., & Cho, Y. K. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.042 · Cited by 61
Zhang, H., Wang, Y., Chen, C., Lu, Y., & Wang, N. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001513 · Cited by 60
Fukunaga, S., Nakano, D., Kawaguchi, T., Eslam, M., Ouchi, A., Nagata, T., Kuroki, H., Kawata, H., Hirohiko, A. B. E., Nouno, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115462 · Cited by 59
Self-citationChun, H. S., Kim, M. N., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., & Kim, S. U. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12754 · Cited by 58
Liu, S., Wang, J., Wu, S., Niu, J., Zheng, R., Bie, L., Xin, Z., Wang, S., Lin, H., Zhao, Z., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154779 · Cited by 56
Huang, S., Su, H.-J., Kao, J., Tseng, T., Yang, H., Su, T., Chen, P., & Liu, C. (2021) · Gut and Liver · doi:10.5009/gnl20218 · Cited by 55
Pal, P., Palui, R., & Ray, S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1584 · Cited by 55
Nachit, M., Lanthier, N., Rodriguez, J., Neyrinck, A. M., Cani, P. D., Bindels, L. B., Hiel, S., Pachikian, B. D., Tréfois, P., Thissen, J., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100323 · Cited by 52
Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
Hashimoto, Y., Hamaguchi, M., Okamura, T., Nakanishi, N., Obora, A., Kojima, T., & Fukui, M. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13678 · Cited by 52
Wu, Y., Kumar, R., Wang, M.-F., Singh, M., Huang, J., Zhu, Y., & Lin, S. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i34.5753 · Cited by 49
Self-citationSemmler, G., Wernly, S., Bachmayer, S., Leitner, I., Wernly, B., Egger, M., Schwenoha, L., Datz, L., Balcar, L., Semmler, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab339 · Cited by 48
Cai, J., Lin, C., Lai, S., Liu, Y., Liang, M., Qin, Y., Liang, X., Tan, A., Gao, Y., Lu, Z., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01568-9 · Cited by 46
Shao, C. X., Ye, J., Dong, Z., Li, F., Lin, Y., Liao, B., Feng, S., & Zhong, B. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211033119 · Cited by 43
The metabolic profiles and body composition of lean metabolic associated fatty liver disease
Cheng, Y., Kao, J., & Wang, C. (2021) · Hepatology International · doi:10.1007/s12072-021-10147-0 · Cited by 36
Chen, V. L., Yeh, M., Yang, J. D., Leong, J., Huang, D. Q., Toyoda, H., Chen, Y., Guy, J. E., Maeda, M., Tsai, P., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1606 · Cited by 33
Self-citationLiu, H., Cao, Y., Jin, J., Guo, Y., Zhu, C., Wu, N., Gao, Y., Xu, R., Dong, Q., Zheng, M., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10252-0 · Cited by 32
Fujii, H., Fukumoto, S., Enomoto, M., Uchida‐Kobayashi, S., Kimura, T., Tamori, A., Nadatani, Y., Takashima, S., Nishimoto, N., & Kawada, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-93435-x · Cited by 31
Feng, L., Zhao, Y. Y., & Wang, W. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051218 · Cited by 28
Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection
Lin, Y., Lin, S.-H., Wang, C., Lin, C., Chen, D.-W., Chuang, C., Huang, P., Hung, C., Yang, S.-Y., Cho, W.-R., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080684 · Cited by 26
Self-citationWang, M.-F., Wan, B., Wu, Y., Huang, J., Zhu, Y., & Li, Y.-B. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i4.336 · Cited by 24
MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
Huang, J., Xue, W., Wang, M.-F., Wu, Y., Singh, M., Zhu, Y., Kumar, R., & Lin, S. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s316096 · Cited by 21
Self-citationKemp, W. W., Clayton‐Chubb, D., Majeed, A., Glenister, K., Magliano, D. J., Lubel, J. S., Bourke, L., Simmons, D. S., & Roberts, S. K. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15723 · Cited by 17
Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study
Baratta, F., Ferro, D., Pastori, D., Colantoni, A., Cocomello, N., Coronati, M., Angelico, F., & Ben, M. D. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18178993 · Cited by 15
Wang, Z., Bertot, L. C., Jeffrey, G. P., Joseph, J., Garas, G., de Boer, B., Huang, Y., MacQuillan, G. C., Wallace, M., Smith, B. W., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.040 · Cited by 14
Targher, G., & Byrne, C. D. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.71 · Cited by 11
Tomar, A., Bhardwaj, A., Choudhury, A. K., & Bhattacharyya, D. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_412_21 · Cited by 11
Park, H., Yoon, E. L., Kim, M., Kim, J. H., Cho, S., Jun, D. W., & Nah, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194625 · Cited by 9
Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
Cao, W., Xu, Y., Shen, Y., Wang, Y., Ma, X., & Bao, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s328206 · Cited by 7
Non‐alcoholic fatty liver disease (NAFLD) in Asia—More efforts are needed
Li, J., & Nguyen, M. H. (2020) · Liver International · doi:10.1111/liv.14657 · Cited by 3
Cited by
The global burden of metabolic disease: Data from 2000 to 2019
Chew, N. W. S., Ng, C. H., Tan, D. J. H., Kong, G., Lin, C., Chin, Y. H., Lim, W. H., Huang, D. Q., Quek, J., Fu, C. E., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.02.003 · Cited by 799
Self-citationTargeting MASLD and MASH in the US Hispanic/Latino Population: A Review
Cumpian, N. A., Gutierrez, J. A., Wu, W., & Saab, S. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.4769 · Cited by 22
Metadata
- Authors
- Chan, K. E., Koh, T. J. L., Tang, A. S. P., Quek, J., Yong, J. N., Tay, P., Tan, D. J. H., Lim, W. H., Lin, S. Y., Huang, D., Chan, M., Khoo, C. M., Chew, N. W. S., Kaewdech, A., Chamroonkul, N., Dan, Y. Y., Noureddin, M., Muthiah, M., Eslam, M., & Ng, C. H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2022-05-19
- Volume
- 107
- Issue
- 9
- Pages
- 2691-2700
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4280586590
- Cited by
- 315
- References
- 84
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.